Acquired von Willebrand syndrome: from diagnosis to treatment

Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Cae...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pathologie biologie (Paris) 2009-11, Vol.57 (7-8), p.536-542
Hauptverfasser: Bustany, S, Gautier, P, Lequerrec, A, Troussard, X, Ollivier, Y, Borel-Derlon, A
Format: Artikel
Sprache:fre
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 542
container_issue 7-8
container_start_page 536
container_title Pathologie biologie (Paris)
container_volume 57
creator Bustany, S
Gautier, P
Lequerrec, A
Troussard, X
Ollivier, Y
Borel-Derlon, A
description Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.
doi_str_mv 10.1016/j.patbio.2008.11.005
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734142464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734142464</sourcerecordid><originalsourceid>FETCH-LOGICAL-p140t-fae4934860023ecdc488b5a19be4bf4f05d200d509da724dcec715a3c65283623</originalsourceid><addsrcrecordid>eNo1j01LwzAYx4Mgbk6_gUhunlrzNGmbCh7G8GUw2EXxWNLkqWS0TZekwr69Befpd_nxfyHkDlgKDIrHQzqq2FiXZozJFCBlLL8gSygLmXAAsSDXIRwYgxIEXJEFVFBxUckleV7r42Q9GvrjBvpluw4brwZDw2kw3vX4RNsZ1Fj1PbhgA42ORo8q9jjEG3LZqi7g7Zkr8vn68rF5T3b7t-1mvUtGECwmrUIx98mCsYyjNlpI2eQKqgZF04qW5WYebnJWGVVmwmjUJeSK6yLPJC8yviIPf7mjd8cJQ6x7GzR2nRrQTaEuuQCRiULM5v3ZnJoeTT162yt_qv8f818Jolfj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734142464</pqid></control><display><type>article</type><title>Acquired von Willebrand syndrome: from diagnosis to treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bustany, S ; Gautier, P ; Lequerrec, A ; Troussard, X ; Ollivier, Y ; Borel-Derlon, A</creator><creatorcontrib>Bustany, S ; Gautier, P ; Lequerrec, A ; Troussard, X ; Ollivier, Y ; Borel-Derlon, A</creatorcontrib><description>Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.</description><identifier>EISSN: 1768-3114</identifier><identifier>DOI: 10.1016/j.patbio.2008.11.005</identifier><identifier>PMID: 19193498</identifier><language>fre</language><publisher>France</publisher><subject>Age of Onset ; Aged ; Factor VIII - analysis ; Female ; Hemorrhage - etiology ; Hemostasis ; Humans ; Male ; Middle Aged ; Paraproteinemias - complications ; Phenotype ; Prothrombin Time ; von Willebrand Disease, Type 2 - etiology ; von Willebrand Disease, Type 2 - immunology ; von Willebrand Disease, Type 2 - therapy ; von Willebrand Factor - analysis ; von Willebrand Factor - genetics ; von Willebrand Factor - immunology</subject><ispartof>Pathologie biologie (Paris), 2009-11, Vol.57 (7-8), p.536-542</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19193498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bustany, S</creatorcontrib><creatorcontrib>Gautier, P</creatorcontrib><creatorcontrib>Lequerrec, A</creatorcontrib><creatorcontrib>Troussard, X</creatorcontrib><creatorcontrib>Ollivier, Y</creatorcontrib><creatorcontrib>Borel-Derlon, A</creatorcontrib><title>Acquired von Willebrand syndrome: from diagnosis to treatment</title><title>Pathologie biologie (Paris)</title><addtitle>Pathol Biol (Paris)</addtitle><description>Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.</description><subject>Age of Onset</subject><subject>Aged</subject><subject>Factor VIII - analysis</subject><subject>Female</subject><subject>Hemorrhage - etiology</subject><subject>Hemostasis</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paraproteinemias - complications</subject><subject>Phenotype</subject><subject>Prothrombin Time</subject><subject>von Willebrand Disease, Type 2 - etiology</subject><subject>von Willebrand Disease, Type 2 - immunology</subject><subject>von Willebrand Disease, Type 2 - therapy</subject><subject>von Willebrand Factor - analysis</subject><subject>von Willebrand Factor - genetics</subject><subject>von Willebrand Factor - immunology</subject><issn>1768-3114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LwzAYx4Mgbk6_gUhunlrzNGmbCh7G8GUw2EXxWNLkqWS0TZekwr69Befpd_nxfyHkDlgKDIrHQzqq2FiXZozJFCBlLL8gSygLmXAAsSDXIRwYgxIEXJEFVFBxUckleV7r42Q9GvrjBvpluw4brwZDw2kw3vX4RNsZ1Fj1PbhgA42ORo8q9jjEG3LZqi7g7Zkr8vn68rF5T3b7t-1mvUtGECwmrUIx98mCsYyjNlpI2eQKqgZF04qW5WYebnJWGVVmwmjUJeSK6yLPJC8yviIPf7mjd8cJQ6x7GzR2nRrQTaEuuQCRiULM5v3ZnJoeTT162yt_qv8f818Jolfj</recordid><startdate>200911</startdate><enddate>200911</enddate><creator>Bustany, S</creator><creator>Gautier, P</creator><creator>Lequerrec, A</creator><creator>Troussard, X</creator><creator>Ollivier, Y</creator><creator>Borel-Derlon, A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200911</creationdate><title>Acquired von Willebrand syndrome: from diagnosis to treatment</title><author>Bustany, S ; Gautier, P ; Lequerrec, A ; Troussard, X ; Ollivier, Y ; Borel-Derlon, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p140t-fae4934860023ecdc488b5a19be4bf4f05d200d509da724dcec715a3c65283623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2009</creationdate><topic>Age of Onset</topic><topic>Aged</topic><topic>Factor VIII - analysis</topic><topic>Female</topic><topic>Hemorrhage - etiology</topic><topic>Hemostasis</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paraproteinemias - complications</topic><topic>Phenotype</topic><topic>Prothrombin Time</topic><topic>von Willebrand Disease, Type 2 - etiology</topic><topic>von Willebrand Disease, Type 2 - immunology</topic><topic>von Willebrand Disease, Type 2 - therapy</topic><topic>von Willebrand Factor - analysis</topic><topic>von Willebrand Factor - genetics</topic><topic>von Willebrand Factor - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bustany, S</creatorcontrib><creatorcontrib>Gautier, P</creatorcontrib><creatorcontrib>Lequerrec, A</creatorcontrib><creatorcontrib>Troussard, X</creatorcontrib><creatorcontrib>Ollivier, Y</creatorcontrib><creatorcontrib>Borel-Derlon, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pathologie biologie (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bustany, S</au><au>Gautier, P</au><au>Lequerrec, A</au><au>Troussard, X</au><au>Ollivier, Y</au><au>Borel-Derlon, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired von Willebrand syndrome: from diagnosis to treatment</atitle><jtitle>Pathologie biologie (Paris)</jtitle><addtitle>Pathol Biol (Paris)</addtitle><date>2009-11</date><risdate>2009</risdate><volume>57</volume><issue>7-8</issue><spage>536</spage><epage>542</epage><pages>536-542</pages><eissn>1768-3114</eissn><abstract>Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.</abstract><cop>France</cop><pmid>19193498</pmid><doi>10.1016/j.patbio.2008.11.005</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1768-3114
ispartof Pathologie biologie (Paris), 2009-11, Vol.57 (7-8), p.536-542
issn 1768-3114
language fre
recordid cdi_proquest_miscellaneous_734142464
source MEDLINE; Elsevier ScienceDirect Journals
subjects Age of Onset
Aged
Factor VIII - analysis
Female
Hemorrhage - etiology
Hemostasis
Humans
Male
Middle Aged
Paraproteinemias - complications
Phenotype
Prothrombin Time
von Willebrand Disease, Type 2 - etiology
von Willebrand Disease, Type 2 - immunology
von Willebrand Disease, Type 2 - therapy
von Willebrand Factor - analysis
von Willebrand Factor - genetics
von Willebrand Factor - immunology
title Acquired von Willebrand syndrome: from diagnosis to treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T05%3A17%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired%20von%20Willebrand%20syndrome:%20from%20diagnosis%20to%20treatment&rft.jtitle=Pathologie%20biologie%20(Paris)&rft.au=Bustany,%20S&rft.date=2009-11&rft.volume=57&rft.issue=7-8&rft.spage=536&rft.epage=542&rft.pages=536-542&rft.eissn=1768-3114&rft_id=info:doi/10.1016/j.patbio.2008.11.005&rft_dat=%3Cproquest_pubme%3E734142464%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734142464&rft_id=info:pmid/19193498&rfr_iscdi=true